Concise Review

Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies

Masami Suzuki¹, Chie Kato¹, and Atsuhiko Kato¹

¹Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan

Abstract: Antibodies can swiftly provide therapeutics to target disease-related molecules discovered in genomic research. Antibody engineering techniques have been actively developed and these technological innovations have intensified the development of therapeutic antibodies. From the mid-1990’s, a series of therapeutic antibodies were launched that are now being used in clinic. The disease areas that therapeutic antibodies can target have subsequently expanded, and antibodies are currently utilized as pharmaceuticals for cancer, inflammatory disease, organ transplantation, cardiovascular disease, infection, respiratory disease, ophthalmologic disease, and so on. This paper briefly describes the modes of action of therapeutic antibodies. Several non-clinical study results of the pathological changes induced by therapeutic antibodies are also presented to aid the future assessment of the toxic potential of an antibody developed as a therapeutic. (DOI: 10.1293/tox.2015-0031; J Toxicol Pathol 2015; 28: 133–139)

Key words: therapeutic antibody, mode of action, pathological findings, toxicity study

Antibodies can swiftly provide therapeutics to target the disease-related molecules that have been discovered in genomic research because 1) the high level of specificity and affinity to the target molecule or antigen achieves a high level of efficacy and fewer adverse events, 2) their ability to target diverse molecules and the modes of action of the antibodies allow them to be applied to a wide range of therapeutic targets, and 3) modification and refinement by genetic engineering technology and the establishment of recombinant manufacturing technology has made industrial manufacturing possible.

Development of therapeutic antibodies boomed in the 1980’s, and the first therapeutic antibody, a mouse antibody, was launched in 1986 as an immunosuppressive agent used during organ transplantation¹⁻³. Although problems, such as mouse antibodies expressing antigenicity in humans, prevented any therapeutic antibodies being launched in the next 10 years, antibody engineering techniques continued to be actively developed and resulted in techniques to produce chimeric antibodies and humanized antibodies from mouse antibodies ⁴⁻⁸. In chimeric antibodies, 33% of the structure originates from mouse, with variable regions from mouse and constant regions from human, and in humanized antibodies, up to 90% of the structure originates from human, with only the antigen binding site in the variable region (complementarity-determining region) originating from mouse. Furthermore, new techniques made it possible to obtain human antibodies from human antibody phage libraries and human antibody–producing mice⁹⁻¹⁵. These technological innovations intensified the development of therapeutic antibodies, and from the mid-1990’s, a series of therapeutic antibodies were launched that are now being used in clinic. The disease areas that therapeutic antibodies can target have subsequently expanded, and antibodies are currently utilized as pharmaceuticals for cancer, inflammatory disease, organ transplantation, cardiovascular disease, infection, respiratory disease, ophthalmologic disease, and so on (Table 1).

This paper briefly describes the modes of action of therapeutic antibodies. Several non-clinical study results of the pathological changes induced by therapeutic antibodies are also presented to aid the future assessment of the toxic potential of an antibody that is being developed as a therapeutic.

Mechanisms of Action of Therapeutic Antibodies

The efficacy of therapeutic antibodies stems from various natural functions of antibodies — neutralization, antibody-dependent cell-mediated cytotoxic (ADCC) activity, or complement-dependent cytotoxic (CDC) activity —, or the antibody can be utilized as a drug delivery carrier (missile therapy)¹¹ (Fig. 1).

Neutralization: Many therapeutic antibodies utilize neutralization to block the pathophysiological function of
| Scientific name | Trade name | Approval | Origin and isotype | Target | MoA* | Licensed indication |
|-----------------|------------|----------|--------------------|--------|------|---------------------|
| **Cancer**      |            |          |                    |        |      |                     |
| Rituximab       | Rituxan, MabThera Herceptin | 1997 | Chimeric IgG1 | CD20 | ADCC, CDC, CDC | B cell non-Hodgkin lymphoma |
| Trastuzumab     | Herceptin | 1998 | Humanized IgG1 | HER-2 | ADCC, CDC, CDC | HER-2 positive breast cancer |
| Gemtuzumab ozogamicin Alectumab | Mylotarg | 2000 | Humanized IgG4 | CD33 ADC | Targeting | Leukemia |
| Campath, MabCampath Zevalin | 2001 | Humanized IgG1 | CD52 | ADCC, CDC, Blocking | NHL |
| Ibritumomab tiuxetan | 2002 | Murine IgG1 | CD20 RIT | Targeting | NHL |
| Tositumomab iodine 131 | Bexxar | 2003 | Murine IgG2 | CD20 RIT | Targeting | NHL |
| Cetuximab       | Erbitux    | 2004 | Chimeric IgG1 | EGFR | ADCC, CDC, Blocking | Colorectal, head and neck cancer |
| Bevacizumab     | Avastin    | 2004 | Humanized IgG1 | VEGF | Blocking | Colorectal, lung, breast cancer |
| Panitumumab     | Vectibix   | 2006 | Human IgG2 | EGFR | Blocking | Colorectal cancer |
| Catumaxomab     | Removab    | 2009 | Chimeric IgG2a/b* | CD3, EpCAM | ADCC, CDC | Malignant ascites |
| Denosumab       | Prolia, Xgeva Arzerra Adcetris | 2010 | Human IgG2 | RANKL | Blocking | Osteoporosis, bone metastasis |
| Brentuximab     | Avastin    | 2009 | Human IgG1 | CD20 | CDC | CLL |
| Vedotinumab     | Avastin    | 2011 | Human IgG1 | CD30 ADC | Targeting | ALCL and Hodgkin lymphoma |
| Pertuzumab      | Perjeta    | 2012 | Humanized IgG1 | CTLA4 | Blocking | Advanced melanoma |
| Mogamulizumab   | Poteligeo  | 2012 | Humanized IgG1 | HER-2 | Blocking | HER-2 positive breast cancer |
| Obinutuzumab    | Gazyva     | 2013 | Humanized & glyco-engineered IgG1 | CD20 | ADCC | T cell leukemia-lymphoma |
| **Inflammation**|            |          |                    |        |      |                     |
| Infliximab      | Remicade   | 1998 | Chimeric IgG1 | TNF | Blocking | RA, ankylosing spondylitis, Crohn’s disease, ulcerative colitis |
| Adalimumab      | Humira     | 2002 | Human IgG1 | TNF | Blocking | RA, Crohn’s disease, plaque psoriasis, Castleman’s syndrome, RA |
| Tolizumab       | Actemra, Roactemra | 2005 | Humanized IgG1 | IL-6R | Blocking | Rheumatoid arthritis, Crohn’s disease |
| Certolizumab pegol | Camlia | 2008 | Humanized Fab | TNF | Blocking | Rheumatoid arthritis, Crohn’s disease |
| Canakinumab     | Ilaris     | 2009 | Human IgG1 | IL-1β | Blocking | Muckle-Wells syndrome |
| Golimumab       | Simponi    | 2009 | Human IgG1 | TNF | Blocking | RA, psoriatic arthritis, ankylosing spondylitis |
| Belimumab       | Benlysta   | 2011 | Human IgG1 | Bacillus anthracis protective antigen | Blocking | Systemic lupus erythematosus, Inhalation anthrax from bacillus anthracis |
| Raxibacumab     | Raxibacumab | 2012 | Human IgG1 | IL-6 | Blocking | Castleman’s disease |
| Siltuximab      | Sylvant    | 2014 | Chimeric IgG1x | | Blocking | Transplant rejection |
| **Transplant**  |            |          |                    |        |      |                     |
| Muromonab-CD3   | Orthoclone OKT3 | 1986 | Murine IgG2a | CD3 | Blocking | Transplant rejection |
| Daclizumab      | Zenapax    | 1997 | Humanized IgG1 | CD25 | Blocking | Prophylaxis for transplant rejection |
| Basiliximab     | Simulect   | 1998 | Chimeric IgG1 | CD25 | Blocking | Prophylaxis for transplant rejection |
In this case, antibodies bind to the ligand or receptor that is expressed on the cell surface and block the target signaling pathway. When the signaling in the tumor through these ligands or receptors is diminished, it can result in cellular activity being lost, proliferation being inhibited, pro-apoptotic programs being activated, or cells being resensitized to cytotoxic agents16.

**Fig. 1.** Mechanisms of action of therapeutic antibodies.

| Scientific name | Trade name | Approval | Origin and isotype | Target | MoA* | Licensed indication |
|-----------------|------------|----------|--------------------|--------|------|---------------------|
| Abciximab       | ReoPro     | 1994     | Chimera Fab        | GPIIb/IIIa | Blocking | Prevention of cardiac ischemic complications |
| Palivizumab     | Synagis    | 1998     | Humanized IgG1     | RSV F protein | Blocking | Prevention of RSV infection in neonates |
| Omalizumab      | Xolair     | 2003     | Humanized IgG1     | IgE    | Blocking | Severe asthma |
| Efalizumab***   | Raptiva    | 2003     | Humanized IgG1     | CD11a  | Blocking | Psoriasis |
| Natalizumab     | Tysabri    | 2004     | Humanized IgG4     | α4β1 integrin | Blocking | Multiple sclerosis |
| Ranibizumab     | Lucentis   | 2006     | Humanized Fab      | VEGF   | Blocking | Macular degeneration |
| Eculizumab      | Soliris    | 2007     | Humanized IgG2/4   | Complement 5 | Blocking | Paroxysmal nocturnal hemoglobinuria, atypical hemolytic-uremic syndrome |
| Ustekinumab     | Stelara    | 2009     | Human IgG1         | IL12, IL23- p40 | Blocking | Plaque psoriasis |

*MOA, mode of action; **bi-specific antibody; ***Approved in 2003 and withdrawn from the market in 2009 because of side effect. CD, cluster of differentiation; CDC, complement-dependent cytotoxicity; ADCC, antibody-dependent cell-mediated cytotoxicity; HER-2, human epidermal growth factor receptor 2; ADC, antibody drug conjugate; B-CLL, B-cell chronic lymphocytic leukemia; RIT, radioimmunotherapy; NHL, non-Hodgkin lymphoma; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor; EpCAM, epithelial cell adhesion molecule; RANKL, receptor activator of nuclear factor kappa-B ligand; ALCCL, anaplastic large cell lymphoma; CTLA4, cytotoxic T-lymphocyte antigen 4; NSCLC, non-small cell lung cancer; TNF, tumor necrosis factor; RA, rheumatoid arthritis; IL-6R, interleukin 6 receptor; IL-1β, interleukin 1β; BLys, B lymphocyte stimulator; PSA, prostate antigen; RSV, respiratory syncytial virus; IL-12p40, interleukin 12 p40 subunit.
activate the immune-effector cells to lyse the target cell\textsuperscript{17}.

**CDC:** CDC is triggered when the C1 complex binds the antibody–antigen complex, activates a cascade of complement proteins, and causes a complex to form that attacks the membrane. This results in lysis of the target cell\textsuperscript{17}. Both ADCC and CDC are interactions that involve components of the host immune system and, among the therapeutic antibodies being developed for cancer, there are presumably products that utilize more than one mechanism (ADCC, CDC, and neutralizing functions) in their pharmacological actions.

Drug delivery carrier: Antibodies can be applied as drug delivery carriers when conjugated to radioisotopes, toxins, drugs or cytokines\textsuperscript{17}. The advantage of these conjugates over conventional drugs is that cytotoxic agents can be delivered directly and at higher local concentrations to tumor tissues, without causing damage to normal cells.

Antibodies that bind and/or cross-link to target molecules and thus stimulate several signal pathways are also under research. However, these agonistic antibodies have not been placed on the market at this point.

**Pathological Findings Induced by Therapeutic Antibodies in Toxicity Studies**

Below are examples of the histopathological changes induced by therapeutic antibodies in non-clinical studies. As examples of therapeutic antibodies that use neutralization to block the pathophysiological function of their target antigens, we will show the changes caused by an anti-vascular endothelial growth factor (VEGF) antibody and by an epidermal growth factor receptor (EGFR) antibody. For those that use ADCC and CDC, we will give examples of biological reactions to an anti-CD20 antibody.

**Anti-VEGF antibody**

Bevacizumab (Avastin\textsuperscript{®}) is an anti-VEGF humanized monoclonal antibody. It binds to VEGF and blocks VEGF from uniting with its receptors (VEGFR-1 and -2), which then blocks the signal transduction of VEGF\textsuperscript{15}. VEGF is the main factor that controls angiogenesis, and its expression is increased in most human tumors and is related to tumor proliferation/metastasis. Hence, bevacizumab was approved for colorectal cancer, non-small cell lung cancer except squamous cell carcinoma, breast cancer, and so on\textsuperscript{18}. Because the therapeutic blocks all the signaling transduced by VEGF, angiogenesis is inhibited in normal organs as well as in tumors.

Cynomolgus monkeys treated repeatedly with bevacizumab via intravenous injection exhibited several pathologic adverse effects on the epiphyseal growth plate, ovary, and uterus\textsuperscript{19}. Lesions on the epiphyseal growth plate were characterized by a linear cessation of growth line and chondrocyte hyperplasia\textsuperscript{20}. In the ovary, arrested follicular development and absent corpora lutea were shown, and in the uterus, a decrease in endometrial proliferation and in the number of menstrual cycles were also seen\textsuperscript{19, 21}.

It is well known that vascularization of the epiphyseal growth plate region represents a key mechanism for chondrogenesis (cartilage production) and osteogenesis (bone formation)\textsuperscript{22, 23}. A small-molecule VEGF inhibitor that inhibited angiogenesis in rats showed epiphysial growth plate lesions that were characterized by thickening due to the retention of hypertrophic chondrocytes\textsuperscript{24, 25}. It is reported that vascularization is essential for corpus luteum and endometrial formation\textsuperscript{26–28}, therefore, biological reactions caused by an anti-VEGF antibody are considered to be specific reactions by the target molecule in the organs and tissues in which vascularization was constantly maintained.

**Anti-EGFR antibody**

Cetuximab (Erbitux\textsuperscript{®}) is a recombinant human/mouse chimeric anti-EGFR monoclonal antibody\textsuperscript{29}. Cetuximab binds to EGFR selectively, blocks EGFR from uniting with its ligand, EGF, and then blocks the signal transduction of EGF. EGFR is a transmembrane glycoprotein that is expressed in epithelial tissues and acts as a receptor. Binding of EGFR to EGF induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation and differentiation\textsuperscript{30, 31}. EGFR is expressed in normal tissues and also in many solid tumors, including colorectal cancer. Hence, cetuximab is approved for colorectal cancer and squamous cell carcinoma of the head and neck\textsuperscript{30, 31}.

In cynomolgus monkeys, cetuximab was given by repeated intravenous injection and it resulted in dermatologic lesions characterized by hyperkeratosis, parakeratosis, abscess, and acantholysis with bullosa at the external integument. Similar changes were observed in the epithelial mucosa of the nasal passage, esophagus, and tongue at the highest dose level\textsuperscript{32, 33}. In addition, deaths due to sepsis associated with ulcerative dermatitis were observed in the animals at the highest dose level\textsuperscript{32, 33}.

**Anti-CD20 antibody**

Rituximab (Rituxan\textsuperscript{®}) is a chimeric murine/human monoclonal antibody targeted against the pan-B-cell marker CD20. Rituximab binds to B cells that express CD20 and induces cell death through CDC or ADCC\textsuperscript{34}. CD20 is expressed in non-neoplastic B cells (pre, immature, mature, and activated) and neoplastic cells derived from B cells. Rituximab is indicated for the treatment of patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL) and rheumatoid arthritis\textsuperscript{35–37}.

In a non-clinical study, rituximab was administered to cynomolgus monkeys repeatedly via intravenous injection (1/ week), and changes were found in immune-hematopoietic tissues. The total number of lymphocytes decreased in peripheral blood owing to a decrease of B cells, and atrophy of lymphoid follicles and a decrease of CD20-positive B cells were seen in the spleen and systemic lymph node\textsuperscript{38}. All of the cells affected by cytotoxicity were B cells that express CD20, and the reaction is considered to be specific to the target molecule.
The changes induced by a therapeutic antibody in non-clinical study are thought of as biological reactions that are dependent on the target molecule. For example, with a blocking antibody the changes occur in the tissues and organs in which the targeted pathway functions. With antibodies that target specific ligands, changes are found in organs and tissues that express the receptor of the targeted ligand, and with antibodies that target specific receptors, changes are found in organs and tissues that express the targeted receptor. With a cytotoxic antibody the changes are found in the tissues and organs that express the target molecule.

Although the biological reactions induced by a therapeutic antibody are dependent on the target molecule and the target molecules selected in this paper, VEGFR and EGFR, were expressed broadly in normal tissues, the biological changes were not observed in all the organs and tissues that express the target molecule. With a blocking antibody, differences in the biological reactions may depend not only on expression of the target molecule but also on how the target pathway contributes to maintenance of homeostasis. The existence of alternative systems that compensate for the blocked pathway is thought to be an important factor of toxicologic changes.

Cytotoxicity antibodies are reported to have biological reactions that are not induced in all the cells in which antigen is expressed. We analyzed CDC induction in a non-clinical in vivo model and demonstrated that the biological response to an antibody with a CDC mechanism is regulated not only by the distribution of the target molecule but also by various other factors, ranging from antibody distribution to the nature of the host immune system and the presence of membrane complement regulatory proteins. Hence, when a therapeutic antibody induces cytotoxic change via the host immune system, CDC, or ADCC, the immune regulatory system is an important factor on the occurrence of toxic effects.

**Future Trends of Therapeutic Antibodies and Pathological Evaluation**

Recently, antibody engineering techniques have progressed and it is now possible to create antibodies with a diverse selection of functions, such as antibodies with more efficient and long-lasting neutralizing effects, agents that cause cytotoxicity at lower molecule expression levels, or bispecific antibodies that can recognize two different molecules simultaneously to induce new biological responses. These recent advances along with the discovery of novel target molecules shed light on the possibility of new therapies. As the functions and target molecules of antibodies become more and more diverse, it becomes increasingly necessary to understand how the target molecule functions biologically and what will be the biological response to the modified functions induced by the antibody. The toxicological pathology associated with these issues will also need to be evaluated and researched most carefully.

**Disclosure of Potential Conflicts of Interest:** The authors are employees of Chugai Pharmaceutical Co., Ltd., and declare no other potential conflict of interest.

**References**

1. Buss NA, Henderson SJ, McFarlane M, Shenton JM, and de Haan L. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol. 12: 615–622. 2012. [Medline] [CrossRef]

2. Emmons C, and Hunsicker LG. Muromonab-CD3 (Orthoclone OKT3): the first monoclonal antibody approved for therapeutic use. Iowa Med. 77: 78–82. 1987. [Medline]

3. Goldstein G. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation. Transplant Proc. 19(Suppl 1): 1–6. 1987. [Medline]

4. Morrison SL, Johnson MJ, Herzenberg LA, and Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA. 81: 6851–6855. 1984. [Medline] [CrossRef]

5. Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev. 58: 640–656. 2006. [Medline] [CrossRef]

6. Jones PT, Dear PH, Foote J, Neuberger MS, and Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 321: 522–525. 1986. [Medline] [CrossRef]

7. Boulianne GL, Hozumi N, and Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature. 312: 643–646. 1984. [Medline] [CrossRef]

8. Green LL, Hardy MC, Maynard-Currie CE, Tsuda H, Louie DM, Mendez MJ, Abderrahim H, Noguchi M, Smith DH, Zeng Y, David NE, Sasai H, Garza D, Brenner DG, Hales JF, McGuinness RP, Capon DJ, Klaholz S, and Jakobovits A. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet. 7: 13–21. 1994. [Medline] [CrossRef]

9. Hoet RM, Cohen EH, Kent RB, Rookey K, Schoonbrodt S, Hogan S, Rem L, Frans N, Daukandt M, Pieters H, van Hegelsom R, Neer NC, Nastrig HI, Rondon JJ, Leeds JA, Hufton SE, Huang L, Kashin I, Devlin M, Kuang G, Steu-kers M, Viswanathan M, Nixon AE, Sexton DJ, Hoogenboom HR, and Ladner RC. Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat Biotechnol. 23: 344–348. 2005. [Medline]

10. Jostock T, Vanhove M, Brepoels E, Van Goel R, Daukandt M, Wehnert A, Van Hegelsom R, Dransfield D, Sexton D, Devlin M, Ley A, Hoogenboom H, and Müllerberg J. Rapid generation of functional human IgG antibodies derived from Fab-on-plaque display libraries. J Immunol Methods. 289: 65–80. 2004. [Medline] [CrossRef]

11. Lonberg N, Taylor LD, Harding FA, Trounistine M, Higgins KM, Schramm SR, Kuo CC, Mashayekh R, Wymore K, McCabe JG, Munoz-O’Regan D, O’Donnell SL, Lapachet ESG, Bencechaa T, Fishwild DM, Carmack CE, Kay RM, and Huszar D. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature. 368: 856–859. 1994. [Medline] [CrossRef]
12. McCafferty J, Griffiths AD, Winter G, and Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 348: 552–554. 1990. [Medline] [CrossRef]

13. Vaughn TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, and Johnson KS. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol. 14: 309–314. 1996. [Medline] [CrossRef]

14. Vaughn TJ, Osbourn JK, and Tempest PR. Human antibodies by design. Nat Biotechnol. 16: 535–539. 1998. [Medline]

15. Winter G, Griffiths AD, Hawkins RE, and Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol. 12: 433–455. 1994. [Medline]

16. Cavallo F, Calogero RA, and Forni G. Are oncoantigens suitable targets for anti-tumour therapy? Nat Rev Cancer. 7: 707–713. 2007. [Medline]

17. Zafrir-Lavie I,Michaeli Y, and Reiter Y. Novel antibodies as anticancer agents. Oncogene. 26: 3714–3733. 2007. [Medline] [CrossRef]

18. Lyseng-Williamson KA, and Robinson DM. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer. BioDrugs. 20: 193–195. 2006. [Medline] [CrossRef]

19. Ryan AM, Eppler DB, Hagler KE, Bruner RH, Thomford PJ, Hall RL, Shopp GM, and ONeill CA. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol. 27: 78–86. 1999. [Medline] [CrossRef]

20. Hall AP, Westwood FR, and Wadsworth PF. Review of the effects of anti-angiogenic compounds on the epithelial growth plate. Toxicol Pathol. 34: 131–147. 2006. [Medline] [CrossRef]

21. Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, Chisholm V, Hillan KJ, and Schwall RH. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med. 4: 336–340. 1998. [Medline]

22. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, and Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med. 5: 623–628. 1999. [Medline]

23. Gerber HP, and Ferrara N. Angiogenesis and bone growth. Trends Cardiovasc Med. 10: 223–228. 2000. [Medline] [CrossRef]

24. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, and Wadsworth PF. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. 60: 970–975. 2000. [Medline]

25. Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossim AM, Emerson E, Finkelstein M, Floyd E, Harriman S, Atherton J, Hillerman S, Soderstrom C, Kou K, Gant T, Noe MC, Foster B, Rastinejad F, Marx MA, Schaeffer T, Whalen PM, and Roberts WG. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res. 63: 7301–7309. 2003. [Medline]

26. Maas JW, Groothuis PG, Dunselman GA, de Goeij AF, Struyker Boudier HA, and Evers JL. Endometrial angiogenesis throughout the human menstrual cycle. Hum Reprod. 16: 1557–1561. 2001. [Medline] [CrossRef]

27. Reynolds LP, Grazul-Bilska AF, and Redmer DA. Angiogenesis in the female reproductive organs: pathological implications. Int J Exp Pathol. 83: 151–163. 2002. [Medline] [CrossRef]

28. Robinson RS, Woad KJ, Hammond AJ, Laird M, Hunter MG, and Mann GE. Angiogenesis and vascular function in the ovary. Reproduction. 138: 869–881. 2009. [Medline] [CrossRef]

29. Blick SK, and Scott LJ. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs. 67: 2585–2607. 2007. [Medline] [CrossRef]

30. Harding J, and Burtness B. Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. Drugs Today (Barc). 41: 107–127. 2005. [Medline]

31. Cohen MH, Chen H, Shord S, Fuchs C, He K, Zhao H, Sickafuse S, Keegan F, and Pazdur R. Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. Oncologist. 18: 460–466. 2013. [Medline]

32. Pharmaceuticals and medical devices agency. Interview form: Erbitux. 2015, from Pharmaceuticals and medical devices agency website: http://www.info.pmda.go.jp/go/interview/form: Erbitux. 2015, from Pharmaceuticals and medical devices agency: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125084s262lbl.pdf.

33. Cerny T, Borisch B, Introna M, Johnson P, and Rose AL. Mechanism of action of rituximab. Anticancer Drugs. 13(Suppl 2): S3–S10. 2002. [Medline] [CrossRef]

34. Leget GA, and Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol. 10: 548–551. 1998. [Medline] [CrossRef]

35. Ploosker GL, and Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 63: 803–843. 2003. [Medline] [CrossRef]

36. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burnmester G, Dörner T, Ferraccioli G, Gottenberg JE, Issacs J, Kvien TK, Mariette X, Martin-Mola E, Pavelka K, Tak PP, van der Heijde D, van Vollenhoven RF, and Emery P. Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 70: 909–920. 2011. [Medline]

37. Mao CP, Bravormay MR, Dabbagh K, Birnbóck HF, Richter WF, and Del Nagro CJ. Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. PLoS ONE. 8: e60533. 2013. [Medline] [CrossRef]

38. Toma MB, and Medina PJ. Update on targeted therapy - Focus on monoclonal antibodies. J Pharm Pract. 21: 4–16. 2008. [CrossRef]

39. Hansel TT, Kropshofer H, Singer T, Mitchell JA, and George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 9: 325–338. 2010. [Medline]

40. Horvat M, Kloboves Prevodnik V, Lavrencak J, and
42. Perz J, Topaly J, Fruehauf S, Hensel M, and Ho AD. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 43: 149–151. 2002. [Medline]

43. Kato C, Kato A, Adachi K, Fujii E, Isobe K, Matsushita T, Watanabe T, and Suzuki M. Anti-Thy-1 Antibody-mediated Complement-dependent Cytotoxicity is Regulated by the Distribution of Antigen, Antibody and Membrane Complement Regulatory Proteins in Rats. J Toxicol Pathol. 26: 41–49. 2013. [Medline] [CrossRef]

44. Kato C, Kato A, Adachi K, Fujii E, Isobe K, Watanabe T, Ito T, and Suzuki M. Expression of Membrane Complement Regulatory Proteins Crry and CD55 in Normal Rats. J Toxicol Pathol. 26: 223–226. 2013. [Medline]

45. Igawa T, Mimoto F, and Hattori K. pH-dependent antigen-binding antibodies as a novel therapeutic modality. Biochim Biophys Acta. 1844: 1943–1950. 2014. [Medline]

46. Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, and Hattori K. Engineering the variable region of therapeutic IgG antibodies. MAbs. 3: 243–252. 2011. [Medline] [CrossRef]

47. May C, Sapra P, and Gerber HP. Advances in bispecific biotherapeutics for the treatment of cancer. Biochem Pharmacol. 84: 1105–1112. 2012. [Medline]

48. Liu JK. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Ann Med Surg (Lond). 3: 113–116. 2014. [Medline]